Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer.
Sato-Kaneko F, Yao S, Ahmadi A, Zhang SS, Hosoya T, Kaneda MM, Varner JA, Pu M, Messer KS, Guiducci C, Coffman RL, Kitaura K, Matsutani T, Suzuki R, Carson DA, Hayashi T, Cohen EE.
Sato-Kaneko F, et al. Among authors: suzuki r.
JCI Insight. 2017 Sep 21;2(18):e93397. doi: 10.1172/jci.insight.93397. eCollection 2017 Sep 21.
JCI Insight. 2017.
PMID: 28931759
Free PMC article.